
    
      This is an observational, prospective, single group, multicentre, international study.

      The present study is planned to assess, in a real-world setting, the long-term clinical
      response, functional impairment and quality of life in outpatients with Major Depressive
      Disorder who, according to the physician's judgment, have responded to the acute monotherapy
      (6 to 8 weeks of treatment) with Trazodone once-a-day and are eligible to continue Trazodone
      once-a-day monotherapy according to clinical practice.
    
  